Cancerous Immunoglobulins in Cancer Immunology

Gregory Lee

1UBC Center of Reproductive Health, University of British Columbia, Vancouver, BC, Canada
2Department of Pathology, Shantou University Medical College, Shantou, China

Corresponding author: Gregory Lee, UBC Center for Reproductive Health, University of British Columbia, Vancouver, British Columbia, Canada V6P 6R9, Tel: 1-604-325-4602; E-mail: cyglee@yahoo.com

Received date: November 28, 2014, Accepted date: December 16, 2014, Published date: December 22, 2014

Abstract

The expression of immunoglobulins by cancer cells have been known for two decades. However, the mechanisms of action behind these cancerous immunoglobulins (clG) are not well understood and may be different from immunoglobulins secreted by normal B lymphocytes. Therefore, the structural and functional roles of clG have been actively investigated to resolve this mystery. A monoclonal antibody, RP215, was generated in 1987 and was shown to react with a carbohydrate-associated epitope localized mainly on the heavy chains of clG but not on normal immunoglobulins. The knowledge of clG has been greatly advanced by using RP215 as a unique probe. Not only was RP215 shown to act as an anti-clG to induce apoptosis of cultured cancer cells in vitro/in vivo, it was also shown to elicit complement-dependent cytotoxicity (CDC) reactions to trigger lysis of cancer cells. It has now been established that besides serving to preserve growth/proliferation of cancer cells by capturing growth factors from the human serum, clG may also interact with certain human serum proteins which may be harmful to cancer cells. Thus, the hypothesis of dual functional roles of clG can be adequately explained in cancer immunology. Furthermore, RP215 may also be used to target cancer cells with surface bound clG for development of antibody-based anti-cancer drugs, provided that bioequivalent humanized RP215 is available for preclinical and clinical studies of immunotherapy.

Keywords: RP215; CA215; Cancerous immunoglobulins; Human serum proteins; Pro-cancer; Anti-cancer

Abbreviations

ALP: Alkaline Phosphatase; clG: Cancerous Immunoglobulins; CDC: Complement-Dependent Cytotoxicity; HRP: Horseradish Peroxidase; IHC: Immunohistochemical; IgSF: Immunoglobulin Superfamily; LC-MS/MS: Liquid Chromatography Tandem Mass Spectrometry; MALDI-TOF MS: Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry; Mab: Monoclonal Antibody; NFκB: Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells; RT-PCR: Reverse Transcriptase Polymerase Chain Reaction; TCRs: T Cell Receptors; TLRs: Toll-Like Receptors.

Background Information

Although the expressions of immunoglobulins by cancer cells have been known for decades, their potential functional roles in the immunology of cancer cells are not fully recognized [1-17]. In comparison, in conventional immunology, the mechanisms of action behind immunoglobulins secreted by B cells have been fully elucidated for decades [18].

As early as 1987, a Mab designated as RP215 was generated against the OC-3-VGH ovarian cancer cell line, and later shown by MALDI-TOF MS to recognize a carbohydrate-associated epitope located mainly on the heavy chains of immunoglobulins expressed by almost all cancer cells [8,19-21]. Since then, RP215 has become a unique tool for investigations regarding the functional roles of cancerous immunoglobulins (clG) in cancer cells [20,22-27]. During the last decade, extensive biological and immunological studies have been conducted by use of this antibody probe. Results of such studies revealed dual functional roles of clG for the growth/proliferation and the immune protection of cancer cells in our body’s microenvironment. Therefore, in this review, our research efforts, as well as that of others on subjects related to clG, were summarized to explore the potential roles of clG and their implications in cancer immunology and immunotherapy.

Discovery of Immunoglobulins Expressed By Cancer Cells

In conventional immunology, immunoglobulins of unlimited diversity were known to be secreted by B lymphocytes in response to challenge by antigens, such as foreign pathogens or antigen fragments, upon interactions with antigen-presenting cells. The initial interactions are followed by B cell activation, serial differentiations and diversifications of immunoglobulins through processes of somatic hypermutation, and class switching [18,28].

However, immunoglobulins can also be expressed by and detected on the cancer cell surface or in shed culture media [1,7,9-11,14,16,29-35]. These atypical immunoglobulins can also be expressed in normal hyperplastic epithelial cells, as well as those localized in the immune-privileged sites such as the skin, cervix, esophagus, eye, and placenta [2,5,6,29,36-39]. Control experiments were performed to rule out possible contaminations by the endogenous B cells, such as the absence of the CD19 biomarker [29,31,40]. Single cell RT-PCR was eventually utilized to document their expressions from cancer cells of various tissue origins [1,2,7,8,11].
Following the generation of RP215 Mab and identification of the molecular identity of the cognate antigen, designated as CA215, it has become apparent that RP215 reacts specifically with a carbohydrate-associated epitope located mainly on the heavy chains of immunoglobulins expressed by cancer cells [19,41]. Therefore, the existence of this RP215-specific epitope makes clgG distinguishable from normal human IgG. RP215 has been an invaluable tool to study clgG, especially their functional roles in cancer cells. The results and conclusions of such studies will be described and summarized in the latter sections of this review.

Following the initial discoveries of clgG, extensive biological and immunological studies have been performed by several other laboratories [2,11,13,24,32]. Immunohistochemical studies revealed that immunoglobulins can be expressed by almost all cancerous tissues or cancer cell lines [20]. The functional roles of clgG were initially investigated with anti-human IgG as the probe. It was generally observed that anti-human IgG can induce apoptosis in cancer cell culture and reduce tumor volume in nude mouse animal models [2,11,13,24,32]. These results are consistent with those of siRNA experiments which revealed inhibition of tumor growth in vitro or in vivo [11,32]. Therefore, it was generally believed that immunoglobulins expressed by cancer cells are essential for the growth/proliferation of cancer cells in vitro or in vivo. Consistently, when RP215 was incubated with cultured cancer cells for 24 or 48 hrs, apoptosis was induced to cultured cancer cells at a concentration as low as 1μg/mL. Therefore, RP215 can be a suitable substitute for anti-human IgG for many functional studies of clgG [20,22-27]. Furthermore, RP215 has little cross-reactivity with normal immunoglobulins [42]. Therefore, surface-bound clgG can be a potential target of RP215 immunotherapy of human cancer if humanized forms of RP215 are available for further clinical studies.

Comparative Structural and Molecular Biological Studies between Cancerous and Normal Immunoglobulins

Since the initial observation of the expression of immunoglobulin among cancer cells, numerous reports have been available to document their expressions through biological and immunological studies, including IHC assays, RT-PCR, in situ hybridization, and Western blot assays [20,41,42]. Generally speaking, at the DNA and protein levels in the heavy chain constant regions, immunoglobulins derived from normal B cells or cancer cells are virtually identical [15]. In contrast to a much greater diversity for the heavy chain variable regions of B cell-derived immunoglobulins, the corresponding variable regions of clgG were found to be much more restricted in hypermutations with no class switching observed [43,44]. The promoter used for the gene expressions of clgG was also different from that of B cells (Oct-2 vs. Oct-1) [15,45]. Therefore, it was hypothesized that the cancer cell-derived immunoglobulin gene may have a distinct repertoire and may play a role in carcinogenesis [15]. Following the elucidation of the molecular identity of CA215, the cognate antigen for RP215, it has been documented that RP215 reacts specifically with the carbohydrate-associated epitope located mainly on the heavy chains of immunoglobulins expressed by cancer cells but not in normal immunoglobulins. The structure of the RP215-specific “sugar” epitope of clgG was then elucidated through comprehensive glycoanalysis of CA215 or clgG to be described later.

Carbohydrate-Associated Epitope Recognized by RP215 Monoclonal Antibody

Since the RP215-specific epitope was sensitive to treatment of mild periodate solution, it was initially concluded that a carbohydrate is involved in the epitope recognition by RP215 [22,41]. Upon treatment of cultured cancer cells with tunicamycin, which inhibits the biosynthesis of N-glycans, the RP215-specific epitope was not affected [46]. Therefore, we believe that the RP215-specific sugar epitope is O-linked, but not N-linked.

Furthermore, the immunoactivity of CA215 was strongly inhibited by goat anti-human IgG (Fab) but not by goat anti-human IgG (Fc). This observation seems to indicate that the O-linked glycan recognized by RP215 is located in the variable regions of the immunoglobulin heavy chains and not in the constant region (Fc) of immunoglobulins. Peptide mapping and glycoanalysis of clgG or CA215 were performed to elucidate the O-glycan structure that can be recognized by RP215 [46]. The results seemed to indicate that the O-linked glycans from CA215 and clgG contain trisaccharides with a terminal N-acetyl neuramic acid (NeuAc) as the major glycan component. The glycosyl linkage indicates that the main O-glycan is core I structures with 3-linked and 3,6-linked GalNAcitol (Figure 1) [46]. Therefore, both CA215 and clgG were found to have identical O-linked structures. Since the affinity between the “sugar” epitope and RP215 is exceptionally high (≤1 nM) for any carbohydrate-related epitope, additional amino acid residues may be involved in the coordinated binding to RP215 for the epitope integrity. This assumption remains to be proven by further in-depth glycoanalysis and glycopeptide mapping [46].

Widespread Expressions of T cell Receptors and Immunoglobulin Superfamily Proteins in Cancer Cells

During the course of MALDI-TOF MS analysis of CA215, it was noticed that tryptic fragments of T cell receptors were identified in addition to clgG and many other unidentified IgSF proteins [20,42]. Biological and immunological studies were conducted to demonstrate that both α and β subunits of TCRs are expressed on the surface of more than 80% of cancer cells [20]. At the DNA and protein levels, cancerous TCRs are identical to those in normal T cells. By IHC and Western blot assays, expressions of TCRs in cancer cells can be ascertained. Furthermore, antibodies against TCRs were shown to induce apoptosis and CDC to cancer cells, indicating the surface nature of TCRs on the cancer cell surface. The gene expressions of TCRs among cancer cells were initially documented in 1998, through RT-PCR of single cancer cells [7]. It was not realized until a decade later that the expression of TCRs are widespread among most cancer cells of various tissue origins [20]. At the same time, co-receptors or co-stimulators of TCRs, including CD3, CD4, and CD8 were not
found to be as significantly expressed compared to the high expression level of TCRs [20]. Therefore, TCRs on cancer cells may be different from those on normal T lymphocytes in terms of their mechanisms of action [20]. It remains to be demonstrated whether TCRs on the cancer cell surface serve to recognize any pathogenic peptides or fragments from any cells bearing the major histocompatibility complex (MHC) inside the human body.

**Functional Roles of Cancerous Immunoglobulins**

Cancerous immunoglobulins were found to be essential for the growth/proliferation of cancer cells. This conclusion was mainly based on the fact that IgG-specific siRNA or anti-human IgG inhibit the growth of cancer cells *in vitro* or *in vivo* with nude mouse animal models [20,22-27]. Similarly, RP215, which reacts specifically with the “sugar” epitope of clgG was also shown to induce apoptosis among various cancer cells in culture. In addition, CDC reactions can also be triggered in the presence of complement and anti-human IgG or RP215. Furthermore, as one of the surface-bound antigen receptors, antibodies against TCRs can also induce apoptosis to culture cancer cells and CDC reactions in the presence of complement [47].

**Gene Regulation Studies of Antigen Receptors Expressed By Cancer Cells**

By using semi-quantitative RT-PCR, changes in the regulations of a number of genes were studied in response to treatments of culture cancer cells with antibodies against antigen receptors, notably, anti-human IgG, RP215, and anti-TCR. Since TLRs are critical components for the innate immunity of many cancer cells, the gene regulations of these TLR genes were extensively studied with unrelated cancer cell lines, namely the OC-3-VGH (ovarian) and C-33A (cervical), which were employed as the models [47,48].

Generally speaking, in response to the treatments of antibodies against antigen receptors or RP215 in cancer cells, the NFκB-1 gene was significantly upregulated in both cancer cell lines. Similarly, the TLR-3 gene was also upregulated. In contrast, the genes of TLR-4 and TLR-9 were downregulated significantly [47]. Results of these gene regulation studies seemed to suggest that antigen receptors play important roles to the innate immunity of cancer cells. In addition, when regulations of more than a dozen genes were compared for correlation studies between RP215 and other two antigen receptors, results of high correlations were obtained ($R^2 \geq 0.90-0.95$).

**RP215-Specific Epitope in the Diagnosis of Cancer Metastasis and Immunodiagnostic Applications**

Since the RP215-specific epitope is carbohydrate-associated, the degree of glycosylations in clgG may be relevant to the metastasis of cancer cells. By using IHC, flow cytometry, and/or indirect immunofluorescent assays, RP215 can be utilized as a diagnostic tool in determining proliferation, migration, and metastasis of cancer cells in cancerous tissues and in identifying cancer stem cells [49].

Since CA215 was shown to consist mainly of immunoglobulin heavy chains expressed by cancer cells, both clgG and CA215 can be affinity-isolated and quantitatively determined. CA215 and clgG can also be assayed in human serum specimens through appropriate enzyme immunoassay kits. RP215 and/or anti-human IgG can be used either for capturing or signal detections. Results of such comparative assays for CA215, clgG, and normal human IgG are presented as histograms in Figure 2 [42].

Generally speaking, CA215 and clgG have relatively low immunoactivity when an anti-hlgG/anti-hlgG-ALP EIA system was used to compare with that of human IgG. However, under a RP215/ RP215-HRP or RP215/anti-human IgG-Fc-ALP system, no immunoactivity with human IgG was observed while differential activities of CA215 and clgG were observed. When the enzyme immunoassay was formulated based on the use of the RP215/RP215-HRP system, signal detection of CA215 in human serum specimens was confirmed in patients with different cancers [21]. When the assay results of other known cancer biomarkers are combined with those of CA215 immunomasys, it was generally concluded that positive detection rates of each cancer category were higher than those using single markers alone. For example, alfafetoprotein (AFP) and CA215 can be combined for a better diagnosis of hepatoma [50]. Similarly, the combined use of CA215 and CA25 can significantly improve the detection of ovarian cancer [21,50]. Results of such analyses are presented in Table 1 for different types of cancer in humans.

CA215 and clgG can also be readily detected by Western blot assay with RP215 as the probe in human serum specimens obtained at the advanced stages of many cancers [8,25,42,51]. These cancer patient specimens included those of the esophagus, stomach, breast, colon, and liver. When RP215 was used, clgG from those patient serum specimens can be detected in the Western blot assay based on the 55 kDa molecular weight of IgG heavy chains [41,42]. Thus, it can be confirmed that CA215 consists mainly of clgG which can be recognized by RP215, whereas normal human IgG shows an absence of cross-reactivity to RP215 [24].

![Figure 2: All immunoassay methods involved a 2-step immunoassay with 1hr incubation of CA215, clgG, or hlgG at 37°C, followed by 1hr incubation at 37°C of the detecting antibody. In the RP215/RP215-HRP immunoassay, wells were coated with 20 μg/mL of RP215 and the detecting antibody used was HRP labeled RP215. In the RP215/GahlgG-G-Fc-ALP immunoassay, wells were coated with 20 μg/mL of RP215 and the detecting antibody used was ALP-labeled goat-anti-human IgG. In the GahlgG/GahlgG-Gc-ALP immunoassay, wells were coated with 1 μg/mL GahlgG and the detecting antibody used was ALP-labeled goat-anti-human IgG. Standard errors are presented in each case of the immunoassays. Relative activities are presented using a log scale.](image)
Dual Roles of Cancerous Immunoglobulins in Cancer Immunology

Since the initial observations of immunoglobulins expressed by cancer cells, it was soon demonstrated that cIgG are crucial to the growth/proliferation of cancer cells in vitro and in vivo [10,11,32]. Following the generation of RP215 which specifically recognizes the “sugar” epitope attached to mainly the heavy chains of cIgG, it has become possible to utilize this unique probe to explore all possible functional roles of cIgG. Initially, CA215 and cIgG were affinity-isolated from the shed media of a cultured ovarian cancer cell line, OC-3-VGH, respectively with RP215 and anti-human IgG as the general ligands. The affinity-purified cognate antigens from the shed media of cancer cells were then used as general ligands to affinity-isolate any serum protein components that may be recognized by CA215 and/or cIgG. The majority of those human serum proteins have been previously identified as endogenous proteins which have been demonstrated to have either anti-cancer or pro-cancer properties [52]. They are listed in Table 2, according to their respective pro-cancer or anti-cancer properties. Details will be discussed in the following section.

| CA215 (0.1 Au/ml) | Lung (n) | Liver (n) | Ovary (n) | Esophagus (n) | Breast (n) | Stomach (n) |
|-------------------|----------|-----------|-----------|---------------|------------|-------------|
| I                 | 52% (112)| 74% (58)  | -         | 61% (23)      | 71% (44)   | 60% (30)    |
| II                | 64% (33) | 54% (35)  | -         | 47% (19)      | 95% (20)   | 50% (14)    |
| III               | 97%      | 81%       | -         | 65%           | 96%        | 70%         |
| CEA (5 ng/ml)     |          |           |           |               |            |             |
| I                 | -        | 74% (58)  | -         | -             | -          | -           |
| II                | -        | 50% (40)  | -         | -             | -          | -           |
| III               | -        | 85%       | -         | -             | -          | -           |
| AFP (20 ng/ml)    |          |           |           |               |            |             |
| I                 | -        | 74% (58)  | -         | -             | -          | -           |
| II                | -        | 50% (40)  | -         | -             | -          | -           |
| III               | -        | 85%       | -         | -             | -          | -           |
| CA125 (35 Au/ml)  |          |           |           |               |            |             |
| I                 | 52% (112)| 74% (58)  | 59% (68)  | 61% (23)      | -          | -           |
| II                | 85% (13) | 85% (13)  | 59% (66)  | 50% (12)      | -          | -           |
| III               | 85%      | 92%       | 82%       | 75%           | -          | -           |
| CA19-9 (37 AU/ml) |          |           |           |               |            |             |
| I                 | -        | 74% (58)  | -         | -             | -          | 60% (30)    |
| II                | -        | 55% (22)  | -         | -             | -          | 75% (16)    |
| III               | -        | 82%       | -         | -             | -          | 81%         |
| CA15-3 (30 AU/ml) |          |           |           |               |            |             |
| I                 | -        | -         | -         | -             | 71% (44)   | -           |
| II                | -        | -         | -         | -             | 83% (6)    | -           |
| III               | -        | -         | -         | -             | 83%        | -           |
| β2 microglobulin (2.6 ng/ml) |          |           |           |               |            |             |
| I                 | -        | 74% (58)  | 59% (68)  | -             | -          | -           |
| II                | -        | 56% (16)  | 90% (10)  | -             | -          | -           |
| III               | -        | 81%       | 100%      | -             | -          | -           |
| Cyfra 21-1 (3.3 ng/ml) |          |           |           |               |            |             |
| I                 | 52% (112)| -         | -         | -             | -          | -           |
| II                | 50% (52) | -         | -         | -             | -          | -           |
| III               | 77%      | -         | -         | -             | -          | -           |

Table 1: Comparative positive detection rates of various cancers by CA215-based and other cancer-associated antigen-based enzyme immunoassay kits. I: CA215 only; II: other marker only; III: combined.

These experimental observations are consistent with our early hypothesis of two independent immune systems in the human body and dual roles of immunoglobulins expressed by cancer cells in general [53,54]. One is the traditional immune system, in which B and T cells play key roles in generating antibodies and TCRs with unlimited antigen-related diversity [18]. In contrast, the cancerous immunoglobulins can only be generated with limited hypermutations and no class switching in different cancer cells [43,44]. The limited number of expressed clgG and/or CA215 may be sufficient to react with any key serum components for the growth/proliferation of cancer cells in vivo. At the same time, these clgG may also serve to neutralize any anti-cancer serum proteins which may be harmful and lead to suppression of cancer cells in our normal human body microenvironment [52-54].
Therefore, it can be hypothesized that two separate and independent immune systems can exist in our human body. The normal one is used to fight off potentially harmful foreign pathogens. On the other hand, clgG may serve dual functional roles for the growth/proliferation and immune-protection of cancer cells in vivo [52-54]. Therefore, any strategy resulting in the deactivation of this cancer immune system, including RP215 to target clgG, should lead to effective immunotherapy of relevant cancer in humans.

Table 2: Human serum proteins or fragments detected commonly by CA215 and clgG and cancer-related functional properties.

| Functional property | Protein (molecular weight) | Key notes |
|---------------------|----------------------------|-----------|
| **Pro-cancer**      |                            |           |
| Complement factor H (139 kDa) | Expressed & secreted by many primary tumors & cancer cell lines to protect them from complement-mediated cytolysis [57-59,61,62] | Downregulation sensitizes cells to complement attack & reduces tumor growth [57-60] |
| Serotransferrin (77 kDa) | Important growth factor for cancer cell proliferation [76-78] | Blocking serotransferrin binding to the cancer cell surface inhibits tumor growth in vitro [78,79] |
| Vitronectin (54 kDa) | Inducer of cancer stem cell differentiation in breast & prostatic carcinoma [65,66] | Interacts with the urokinase receptor to induce cancer cell spreading, migration, and growth [67,80] |
| Others:             |                            |           |
| α2 macroglobulin (163 kDa) | [81,82] | |
| C4b binding protein (67 kDa) | [61,83] | |
| CD5 antigen-like protein (38 kDa) | [84] | |
| Complement C3 (187 kDa) | [63,64,85] | |
| Isoform 2 of α-1-antitrypsin (40 kDa) | [88] | |
| Hemopexin (52 kDa) | [87] | |
| **Anti-cancer**     |                            |           |
| Anastelletin | Inhibit tumor growth and metastasis in vitro through inhibiting angiogenesis [72,73] | Inhibits serum dependent cell growth by blocking progression of the cell cycle [86] |
| Apolipoprotein A-1 | Biomarker of ovarian cancer [89] | Net functional effects include a decrease in tumor growth, angiogenesis, metastasis, invasion, & myeloid-derived suppressor cell recruitment, as well as an increase in anti-tumor macrophages & CD8+ T cells cells [74] Apolipoprotein A-1-deficient mice develop tumors quicker than wild-type mice [74] |
| Fibrinogen β chain | First 20 amino acids of the N terminus of the fibrinogen beta chain (843-63) significantly inhibits VEGF-activated adhesion of epithelial cells to the extracellular matrix [71] | In mouse models, inhibits tumor vascularization & increases tumor necrosis [71] |
| Others:             |                            |           |
| 35 kDa inter-α-trypsin inhibitor heavy chain 4 (104 kDa) | [69,90] | |
| Keratin type I cytoskeletal 9 (62 kDa) | [70] | |
| Complement component C4b (193 kDa) | [64,83] | |

Human Serum Protein Components Recognized by ClgG and/or CA215

As stated in the previous section, serum proteins or components which show affinity to clgG and/or CA215 were affinity isolated and analyzed by LC-MS/MS. They were then classified according to their known functional properties as “pro-cancer” or anti-cancer” [52]. Results of such analysis are presented in Table 2 for further investigations and discussions.

Among the pro-cancer serum components detected by CA215 or clgG, the most notable ones include serotransferrin, C4b-binding protein, complement factor H, complement C3, and vitronectin [52]. Some of these pro-cancer serum components have been implicated as important growth factors for cancer cell proliferation, such as serotransferrin, the iron-binding transport protein within the human circulation [55,56]. Other pro-cancer serum components are members of the complement system, such as C4b-binding protein, complement factor H, and complement C3. Cancer cells are capable of binding to C4b-binding protein and complement factor H to protect cancer cells from complement activation [57-61]. In addition, many primary tumors and cancer cell lines have been known to express and secrete complement factor H [57-59,61,62]. Complement C3 has also been found to be synthesized by gastric-derived cancer cell lines [63]. Through production of vascular endothelial growth factor (VEGF) and extracellular matrix reorganization and disintegration, C3 has been
observed to promote cancer development and progression [64]. Vitronectin has been shown to be an inducer of cancer stem cell differentiation in breast and prostatic carcinoma, as well as an inducer of cancer cell spreading, migration, and growth [65-68].

Among the anti-cancer serum components detected by CA215 or clgG, the most notable ones include 35 kDa inter-a-trypsin inhibitor heavy chain 4, anastellin, apolipoprotein A1, fibrinogen β chain and keratin type I cytoskeletal 9 [52]. Many of these anti-cancer serum components have been found to be downregulated in cancerous tissue, including 35 kDa inter-a-trypsin inhibitor heavy chain 4 and keratin type I cytoskeletal 9. Downregulation of 35 kDa inter-a-trypsin inhibitor heavy chain 4 in multiple solid tumors is believed to be associated with tumor initiation and progression [69]. Downregulation of keratin type I cytoskeletal 9 may be correlated with drug sensitivity of cancerous tissues [70]. Other anti-cancer serum components are also involved in inhibiting angiogenesis, such as the fibrinogen β chain, anastellin, and the cardioprotective protein, apolipoprotein A-1. In mouse models, the first 20 amino acids of the N terminus of the fibrinogen β chain (β43-63) have been found to significantly inhibit tumor vascularization and increase tumor necrosis [71]. Anastellin, a fragment of the first type II module of fibronectin, has been found to inhibit tumor growth and metastasis in vivo through its inhibitory effects on angiogenesis [72,73]. Likewise, the cardioprotective protein, apolipoprotein A-1, which is a major protein component of high density lipoprotein (HDL), has been found to decrease angiogenesis, as well as decrease tumor growth, metastasis, invasion, and myeloid derived suppressor cell recruitment [74]. It has also been shown that mice lacking apolipoprotein A-1 were found to develop tumors quicker than wild-type mice [74].

Based on results of the results of this molecular analysis, it can be hypothesized that immunoglobulins expressed on the cancer cell surface may serve as receptors to interact with a variety of human serum protein components which exhibit pro- or anti-cancer properties. Therefore, through its direct or indirect interactions with human serum components, clgM may serve dual roles in cancer cells by promoting cancer cell growth/proliferation, as well as immune protection of cancer cells from harmful agents within the human circulation.

Research and Development of RP215-Based Anti-Cancer Drugs

Since its discovery in 1987, RP215 has been utilized as a unique probe to study clgG and/or CA215, including their biological/immunological characterization among cancer cells [20,41,42]. Subsequently, it was realized that the surface-bound clgG and/or CA215 may be a potential target for cancer immunotherapy by RP215 Mab. RP215 was shown to induce apoptosis and CDC reactions when incubated with cancer cells in vitro and reduce tumor volume in nude mouse animal models [2,11,13,24,32]. The mechanisms of action of RP215’s anti-cancer activity are more or less elucidated. Recently, humanized forms of RP215 have been successfully developed and shown to be bioequivalent to murine RP215 in terms of their relative biological actions in epitope specificity and affinity to cancer cells. Preclinical studies of humanized RP215 are being performed to see if it is qualified as antibody-based anti-cancer drug candidate for treatment of certain types of cancers in humans, especially for ovarian and lung cancer [75].

Acknowledgement

This research program was supported in parts by NRC-IRAP (#743918 and #794354) and by Vancouver Biotech Ltd. Helpful discussions with Dr. Jiang Gu of Shantou University and the editorial assistance of Suefay Liu on this review are acknowledged.

References

1. Babbage G, Ottemansmeer CH, Blaydes J, Stevenson FK, Sahota SS (2006) Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Research. pp. 3996-4000.
2. Chen Z, Gu J (2007) Immunoglobulin G expression in carcinomas and cancer cell lines. FASEB J 21: 2931-2938.
3. Hu D, Duan Z, Li M, Jiayang, Liu H, et al. (2011) Heterogeneity of aberrant immunoglobulin expression in cancer cells. Cell Mol Immunol 8: 479-485.
4. Hu Z, Zheng J, Zhao L, Huang J, et al. (2012) Spontaneous production of immunoglobulin M in human epithelial cancer cells. PLoS One 7: e51423.
5. Huang J, Sun X, Mao Y, Zhu X, Zhang P, et al. (2008) Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse brain neurons. Int J Biochem Cell Biol 40: 1604-1615.
6. Huang J, Zhang L, Ma T, Zhang P, Qiu X (2009) Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse testis and epididymis. J Histochem Cytochem 57: 339-349.
7. Kimoto Y (1998) Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes Chromosomes Cancer 22: 83-86.
8. Lee G, Ge B (2009) Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomark 5: 177-188.
9. Li M, Tang M, Deng X (2001) [Positive immunoglobulin A expression in human epithelial carcinoma cell lines, Zhonghua Zhong Liu Za Zhi 23: 451-453.
10. Li M, Feng DY, Ren W, Zheng L, Zheng H, et al. (2004) Expression of immunoglobulin kappa light chain constant region in normal human cervical epithelial cells. Int J Biochem Cell Biol 36: 2250-2257.
11. Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, et al. (2003) Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells. Cancer Research 64: 688-694.
12. Zhang L, Hu S, Korteweg C, Chen Z, Qiu X, et al. (2012) Expression of immunoglobulin G in esophageal squamous cell carcinomas and its association with tumor grade and Ki67. Hum Pathol 43: 423-434.
13. Zheng H, Li M, Liu H, Ren W, Hu DS, et al. (2007) Immunoglobulin alpha heavy chain derived from human epithelial cancer cells promotes the access of S phase and growth of cancer cells. Cell Biol Int 31: 82-87.
14. Zheng H, Li M, Ren W, Zeng L, Liu HD, et al. (2007) Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. Mol Immunol 44: 2221-2227.
15. Zheng J, Huang J, Mao Y, Liu S, Xun Y, et al. (2009) Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. J Biol Chem 284: 13610-13619.
16. Zhu X, Li C, Sun X, Mao Y, Li G, et al. (2008) Immunoglobulin mRNA and protein expression in human oral epithelial tumor cells. Appl Immunohistochem Mol Morphol 16: 232-238.
17. Yoshimi K, Woo M, Son Y, Baudry M, Thompson RF (2002) IgG-immunostaining in the intact rabbit brain: variable but significant staining of hippocampal and cerebellar neurons with anti-IgG. Brain Res 956: 53-66.
18. Murphy K, Travers P, Walport M (2007) Janeway’s Immunobiology. New York: Garland Science.
19. Lee CY, Shen KW, Sheu FS, Tsang A, Chao KC, et al. (1992) Studies of a tumor-associated antigen, COX, recognized by a monoclonal antibody. Cancer Immunol Immunother 35: 19-26.

20. Lee G, Zhu M, Ge B, Potzold S (2012) Widespread expressions of immunoglobulin superfamily proteins in cancer cells. Cancer Immunol Immunother 61: 89-99.

21. Lee G (2009) Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications. Cancer Biomark 5: 137-142.

22. Lee G, Ge B (2010) Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunol Immunother 59: 1347-1356.

23. Lee G, Zhu M, Ge B, Cheung AP, Chien CH, et al. (2012) Carbohydrate-associated immunodominant epitope(s) of CA215. Immunol Invest 41: 317-336.

24. Lee G, Cheung AP, Ge B, Zhu M, Giolma B, et al. (2012) CA215 and GnRH receptor as targets for cancer therapy. Cancer Immunol Immunother 61: 1805-1817.

25. Lee G, Zhu M, Ge B (2012) Potential monoclonal antibody therapy for the treatment of ovarian cancer. Ovarian Cancer - Basic Science Perspective. Vancouver: 385-406.

26. Lee G, Chu RA, Ting HH (2009) Preclinical assessment of anti-cancer drugs by using RP215 monoclonal antibody. Cancer Biol Ther 8: 161-166.

27. Lee G, Ge B (2012) Implications of apoptosis in cancer immunotherapy. Advances in Bioscience and Biotechnology 3: 679-685.

28. Bassing CH, Swat W, Alt FW (2002) The mechanism and regulation of chromosomal V(D)J recombination. Cell 109 Suppl: S45-55.

29. Chen Z, Qiu X, Gu J (2009) Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. Am J Pathol 174: 1139-1148.

30. Geng LY, Shi ZZ, Dong Q, Cai XH, Zhang YM, et al. (2007) Expression of SNC7, a transcript of the immunoglobulin alpha-1 gene, in human epithelial carcinomas. World J Gastroenterol 13: 2305-2311.

31. Hu D, Zheng H, Liu H, Li M, Ren W, et al. (2008) Immunoglobulin expression and its biological significance in cancer cells. Cell Mol Immunol 5: 319-324.

32. Li M, Zheng H, Duan Z, Liu H, Hu D, et al. (2012) Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. Cell Mol Immunol 9: 54-61.

33. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, et al. (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137.

34. Yang S, Wang M, You W (2002) [Co-expression of immunoglobulin light chain kappa and lambda in gastric carcinoma cell]. Zhonghua Zhong Liu Za Zhi 24: 465-466.

35. Zheng S, Cao J, Geng L (2001) [Structure and expression of colorectal cancer related Immunoglobulin novel gene SNC73]. Zhonghua Yi Xue Za Zhi 81: 485-488.

36. Niu N, Zhang J, Guo Y, Zhao Y, Korteweg C, et al. (2011) Expression and distribution of immunoglobulin G and its receptors in the human nervous system. Int J Biochem Cell Biol 43: 556-563.

37. Niu N, Zhang J, Sun Y, Wang S, Sun Y, et al. (2011) Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: the eye. Cell Mol Life Sci 68: 2481-2492.

38. Zhang S, Mao Y, Huang J, Ma T, Zhang L, et al. (2010) Immunoglobulin gene locus events in epithelial cells of lactating mouse mammary glands. Cell Mol Life Sci 67: 985-994.

39. Zhao Y, Liu Y, Chen Z, Korteweg C, Gu J (2011) Immunoglobulin g (IgG) expression in human umbilical cord endothelial cells. J Histochem Cytochem 59: 474-488.

40. Hu J, Deng Y, Zheng S (2002) Expression of a novel immunoglobulin gene SNC73 in human cancer and its significance. Zhonghua Zhong Liu Za Zhi 24: 38-40.

41. Lee G, Wu Q, Li CH, Ting HH, Chien C-H (2006) Recent studies of a new carbohydrate-associated pan cancer marker, CA215. Journal of Clinical Ligand Assay 47-51.

42. Lee G, Laflamme E, Chien CH, Ting HH (2008) Molecular identity of a pan cancer marker, CA215. Cancer Biol Ther 7: 2007-2014.

43. Early P, Huang H, Davis M, Calame K, Hood L (1980) An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell 19: 981-992.

44. Honjo T, Kinoshita K, Muramatsu M (2002) Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol 20: 165-196.

45. Zhu X, Wu L, Zhang L, Hao P, Zhang S, et al. (2010) Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cell Mol Immunol 7: 279-286.

46. Lee G, Azadi P (2012) Peptide Mapping and Glycoanalysis of Cancer Cell-Expressed Glycoproteins CA215 Recognized by RP215 Monoclonal Antibody. Journal of Carbohydrate Chemistry 31: 10-30.

47. Tang Y, Zhang H, Lee G (2013) Similar Gene Regulation Patterns for Growth Inhibition of Cancer Cells by RP215 or Anti-Antigen Receptors. J Cancer Sci Ther 5: 200-208.

48. Lee G, Huang CY, Zhang H, Yang T (2014) The Relationships between Toll-like Receptors and RP215-associated Immunoglobulins Expressed by Cancer Cells. J Cancer Sci Ther 6: 077-080.

49. Jiang C, Huang T, Wang Y, Huang G, Wan X, et al. (2014) Immunoglobulin G expression in lung cancer and its effects on metastasis. PLoS One 9: e97359.

50. Lee G, Ge B, Huang TK, Zheng G, Duan J, et al. (2010) Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients. Cancer Biomark 6: 111-117.

51. Lee G, Cheung AP, Ge B, Zhu M, Li PP, et al. (2010) Monoclonal Anti-idiotype Antibodies against Carbohydrate-associate Epitope for Anti-Cancer Vaccine Development. J Vaccines Vaccin 1:106.

52. Lee G, Liu S, Huang C-Y (2014) Human serum proteins recognized by CA215 and cancerous immunoglobulins and implications in cancer immunology. Cancer and Clinical Oncology 3: 51-69.

53. Lee G, Huang CY, Tang Y, Zhang H (2014) Potential Roles of Cancerous Immunoglobulins in the Immunology of Cancer Cells. J Clin Cell Immunol 5:200.

54. Lee G, Huang C-Y, Liu S, Chien CH, Chow S-N (2014) Dual roles of cancerous immunoglobulins in cancer immunology. American Journal of Immunology 10: 156-165.

55. Ponka P (1999) Cellular iron metabolism. Kidney Int 55: S2-S11.

56. Schaeffer E, Boissier F, Py MC, Cohen GN, Zakin MM (1989) An example of cell type-specific expression of the human transferrin gene. Role of promoter, negative, and enhancer elements. J Biol Chem 264: 7133-7160.

57. Willecke K, Rezepko R, Nowis D, Legat M, Golab J, et al. (2008) The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer 122: 2030-2037.

58. Ajona D, Hsu YF, Corrales I, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178: 5991-5998.

59. Junninkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, et al. (2000) Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 164: 6075-6081.

60. Ajona D, Castaño Z, Garayoa M, Zudaire E, Pajares MJ, et al. (2004) Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 64: 6310-6318.

61. Holmberg MT, Blom AM, Meri S (2001) Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and Caov-3 ovarian adenocarcinoma cells. J Immunol 167: 935-939.
